Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Nova Eye Medical ( (AU:EYE) ) is now available.
Nova Eye Medical reported record global sales of US$6.1 million for the December 2025 quarter, up 38% year-on-year and 25% on the previous quarter, driven by strong demand for its iTrack technology in the US and accelerating growth in other regions. Last-twelve-month sales reached about US$21 million, growing roughly three times faster than the broader industry, while operating cash outflow was A$1.0 million, including a A$1.2 million working capital investment to support rapid sales expansion; management expects operating cashflow to continue improving as utilisation of iTrack grows and new markets such as China begin commercialising the recently approved iTrack Advance during 2026.
The most recent analyst rating on (AU:EYE) stock is a Hold with a A$0.19 price target. To see the full list of analyst forecasts on Nova Eye Medical stock, see the AU:EYE Stock Forecast page.
More about Nova Eye Medical
Nova Eye Medical Limited is an ASX-listed medical technology company focused on advanced ophthalmic treatment technologies and devices, particularly for glaucoma. Its primary product is the iTrack family of minimally invasive canaloplasty devices, including iTrack Advance, which are used by eye surgeons worldwide, with a strategic emphasis on the United States market due to its size, reimbursement structures and clinical adoption dynamics.
Average Trading Volume: 423,348
Technical Sentiment Signal: Buy
Current Market Cap: A$54.12M
Learn more about EYE stock on TipRanks’ Stock Analysis page.